Due to the key role of tumor necrosis factor-alpha (TNF-alpha) in the pathogenesis of immunoinflammatory diseases, TNF-alpha inhibitors have been successfully developed and used in the clinical treatment of autoimmune disorders. Currently, five anti-TNF-alpha drugs have been approved: infliximab, adalimumab, golimumab, certolizumab pegol and etanercept. Anti-TNF-alpha biosimilars are also available for clinical use. Here, we will review the historical development as well as the present and potential future applications of anti-TNF-alpha therapies, which have led to major improvements for patients with several autoimmune diseases, such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn's disease (CD), ulcerative colitis (UC), psoriasis (PS) and chronic endogenous uveitis. Other therapeutic areas are under evaluation, including viral infections, e.g., COVID-19, as well as chronic neuropsychiatric disorders and certain forms of cancer. The search for biomarkers able to predict responsiveness to anti-TNF-alpha drugs is also discussed.

Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy

Leone, Gian Marco;Mangano, Katia;Nicoletti, Ferdinando;Fagone, Paolo
2023-01-01

Abstract

Due to the key role of tumor necrosis factor-alpha (TNF-alpha) in the pathogenesis of immunoinflammatory diseases, TNF-alpha inhibitors have been successfully developed and used in the clinical treatment of autoimmune disorders. Currently, five anti-TNF-alpha drugs have been approved: infliximab, adalimumab, golimumab, certolizumab pegol and etanercept. Anti-TNF-alpha biosimilars are also available for clinical use. Here, we will review the historical development as well as the present and potential future applications of anti-TNF-alpha therapies, which have led to major improvements for patients with several autoimmune diseases, such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn's disease (CD), ulcerative colitis (UC), psoriasis (PS) and chronic endogenous uveitis. Other therapeutic areas are under evaluation, including viral infections, e.g., COVID-19, as well as chronic neuropsychiatric disorders and certain forms of cancer. The search for biomarkers able to predict responsiveness to anti-TNF-alpha drugs is also discussed.
2023
COVID-19
TNF-α
TNF-α inhibitors
biomarker
biosimilar agents
inflammation
monoclonal antibody
File in questo prodotto:
File Dimensione Formato  
Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 997.12 kB
Formato Adobe PDF
997.12 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/624069
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 30
social impact